Publication: Immunogenicity and efficacy of zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
Issued Date
2020-06-01
Resource Type
ISSN
2076393X
Other identifier(s)
2-s2.0-85086678040
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines. Vol.8, No.2 (2020), 1-20
Suggested Citation
César López-Camacho, Giuditta De Lorenzo, Jose Luis Slon-Campos, Stuart Dowall, Peter Abbink, Rafael A. Larocca, Young Chan Kim, Monica Poggianella, Victoria Graham, Stephen Findlay-Wilson, Emma Rayner, Jennifer Carmichael, Wanwisa Dejnirattisai, Michael Boyd, Roger Hewson, Juthathip Mongkolsapaya, Gavin R. Screaton, Dan H. Barouch, Oscar R. Burrone, Arvind H. Patel, Arturo Reyes-Sandoval Immunogenicity and efficacy of zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines. Vaccines. Vol.8, No.2 (2020), 1-20. doi:10.3390/vaccines8020307 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/57976
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Immunogenicity and efficacy of zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
Author(s)
César López-Camacho
Giuditta De Lorenzo
Jose Luis Slon-Campos
Stuart Dowall
Peter Abbink
Rafael A. Larocca
Young Chan Kim
Monica Poggianella
Victoria Graham
Stephen Findlay-Wilson
Emma Rayner
Jennifer Carmichael
Wanwisa Dejnirattisai
Michael Boyd
Roger Hewson
Juthathip Mongkolsapaya
Gavin R. Screaton
Dan H. Barouch
Oscar R. Burrone
Arvind H. Patel
Arturo Reyes-Sandoval
Giuditta De Lorenzo
Jose Luis Slon-Campos
Stuart Dowall
Peter Abbink
Rafael A. Larocca
Young Chan Kim
Monica Poggianella
Victoria Graham
Stephen Findlay-Wilson
Emma Rayner
Jennifer Carmichael
Wanwisa Dejnirattisai
Michael Boyd
Roger Hewson
Juthathip Mongkolsapaya
Gavin R. Screaton
Dan H. Barouch
Oscar R. Burrone
Arvind H. Patel
Arturo Reyes-Sandoval
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable vaccine candidate for the correct induction of protective immune responses against ZIKV.